Oncology ASCO 2023 – Gregory Lubiniecki With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
